NCT06038474Active, not recruitingPhase 2
Descartes-08 for Patients With Systemic Lupus Erythematosus
Source: ClinicalTrials.gov · Last updated 27 Mar 2026
Brief summary (registry, in English)
This is a Phase II study to evaluate the safety, tolerability and manufacturing feasibility of Descartes-08 CAR T-cells in patients with Systematic Lupus erythematosus (SLE).
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- First submitted
- 8 Sept 2023
- Start date
- 12 Feb 2024
- Primary completion date
- 1 Dec 2026
- Lead sponsor
- Cartesian Therapeutics
- Diseases
- Lupus (SLE)
- NCT number
- NCT06038474
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 6
- From 12 Feb 2024 to the primary completion date, 1 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Active severe lupus nephritis, active severe CNS lupus, and/or neurological symptoms of SLE including headache, seizure, psychosis, and organic brain syndrome (a patient with an incidental headache, deemed unrelated to SLE, may re-screen by telephone upon resolution of the headache);
- Major chronic illness that is not well managed at the time of study entry and in the opinion of the investigator may increase the risk to the patient.
Other
- Patient is pregnant or lactating.
Who the study is looking for
- Patient must be at least 18 years of age.
- Patient must have systemic lupus erythematosus (SLE) at the time of screening.
- Active symptoms despite recent or ongoing immunosuppressive therapy with glucocorticoids and at least 2 other immunosuppressive medications being tried for at least 12 weeks within 24 months of screening.
- At least one of: anti-dsDNA, anti-histone, anti-chromatin, and/or anti-Sm antibodies detectable at screening as assessed by a CLIA-certified laboratory.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Profound Research LLC Coordinator of this site? Confirm its status | Oceanside | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.